Nat Prod Sci.  2019 Dec;25(4):304-310. 10.20307/nps.2019.25.4.304.

Anti-arthritic Effects of Oplopanax elatus in a Rat Model of Rheumatoid Arthritis (Adjuvant-induced Arthritis)

Affiliations
  • 1College of Pharmacy, Kangwon National University, Chuncheon 24341, Korea. hpkim@kangwon.ac.kr
  • 2Department of Bio-Resource Sciences, Kangwon National University, Chuncheon 24341, Korea.
  • 3Bioherb Research Institute, Kangwon National University, Chuncheon 24341, Korea.

Abstract

The stems of Oplopanax elatus (OE) have long been used to treat inflammatory disorders in herbal medicine, and in the previous investigation, OE was found to possess anti-inflammatory activity in lipopolysaccharide-treated macrophages, RAW 264.7 cell. OE reduces inducible nitric oxide (NO) synthase-induced NO production, and interferes with mitogen-activated protein kinase activation pathways. In the present study, the pharmacological action of the water extract of OE was examined to establish anti-arthritic action, using a rat model of adjuvant-induced arthritis (AIA). The water extract of OE administered orally inhibited AIA-induced arthritis at (100 - 300) mg/kg/day. The paw edema was significantly decreased, in combination with reduced production of pro-inflammatory cytokines. The action mechanism includes an inhibition of MAPKs/nuclear transcription factor-κB activation. These new findings strongly suggest that OE possesses anti-arthritic action, and may be used as a therapeutic agent in inflammation-related disorders, particularly in arthritic condition.

Keyword

Oplopanax elatus; rheumatoid arthritis; adjuvant-induced arthritis; mitogen-activated protein kinase

MeSH Terms

Animals
Arthritis
Arthritis, Rheumatoid*
Cytokines
Edema
Herbal Medicine
Macrophages
Models, Animal*
Nitric Oxide
Oplopanax*
Protein Kinases
Rats*
RAW 264.7 Cells
Water
Cytokines
Nitric Oxide
Protein Kinases
Water

Figure

  • Fig. 1 Inhibition of arthritic inflammation by WOE on adjuvant-induced arthritis in rats. (A) Body weight change (n = 6), (B) Changes of rat right hind paw volume (n = 6), % inhibition = [paw volume of AC − (paw volume of test sample − paw volume of C)] / (paw volume of AC − paw volume of C) × 100, (C) Histologic observation of ankle joint of right hind paw, One set of three samples per group is represented here., Hematoxylin and eosin staining, × 40, C (cartilage), S (synovial tissue), cartilage destruction (), cellular infiltration (→), (D) Gene expression of pro-inflammatory molecules (IL-1β, IL-6, and TNF-α) in right hind paw tissue (n = 3), The paw tissues were homogenized, and total RNA were extracted, followed by real-time PCR analysis., Control (C), adjuvant-treated control (AC), adjuvant + WOE 300 mg/kg/day (AW300), adjuvant + WOE 100 mg/kg/day (AW100), adjuvant + prednisolone 5 mg/kg/day (AP5), +P < 0.1, *P < 0.05, **P < 0.01, significantly different from AC.

  • Fig. 2 Effects of WOE on the signaling pathways of arthritic inflammation in adjuvant-induced arthritis rats. (A) Effects of WOE (300 mg/kg/day) on MAPK pathways (p38 MAPK, ERK, and JNK), (B) Effects of WOE (300 mg/kg/day) on nuclear transcription factor activation (NF-κB p65 and c-Jun), Western blot analysis was performed by homogenizing right hind paw tissues in separate parallel experiment. +P < 0.1, significantly different from adjuvant-treated control (n = 3).

  • Fig. 3 Effects of WOE on pro-inflammatory molecules of the serum in adjuvant-induced arthritic rats. The amount of IL-1β, IL-6, TNF-α, and C-reactive protein (CRP) and activity of ALT and AST in the serum of rats treated WOE (100 and 300 mg/kg/day) and prednisolone (5 mg/kg/day) were measured using ELISA kits. ″P < 0.05, significantly different from control; +P < 0.1, *P < 0.05, **P < 0.01, significantly different from adjuvant-treated control.


Reference

1. Crofford LJ. Arthritis Res Ther. 2013; 15:S2.
Article
2. Ong CK, Lirk P, Tan CH, Seymou RA. Clin Med Res. 2007; 5:19–34.
3. Kang S, Tanaka T, Kishimoto T. Int Immunol. 2015; 27:21–29.
4. Kumar S, Bhosle D, Janghel A, Deo S, Raut P, Verma C, Agrawal M, Amit N, Sharma M, Giri T, Tripathi DK, Ajaz A, Alexander A. Res J Pharm Tech. 2015; 8:597–610.
5. Shikov AN, Pozharitskaya ON, Makarov VG, Yang WZ, Guo DA. Chin J Nat Med. 2014; 12:721–729.
6. Zhong Hua Ben Cao Commission. Chinese Materia Medica (Zhong Hua Ben Cao). China: Shanghai Science and Technology Press;1999. p. 5026–5027.
7. Zhang SC, Wang KZ. Acta Pharm Sin. 1980; 15:81–85.
8. Qu SY, Jiang XL, Wu YJ, Wang YH. Chin Tradit Herb Drugs. 1986; 17:25–26.
9. Kim HK, Son KH, Chang HW, Kang SS, Kim HP. Planta Med. 1999; 65:465–467.
10. Choi J, Shin KM, Park HJ, Jung HJ, Kim HJ, Lee YS, Rew JH, Lee KT. Planta Med. 2004; 70:1027–1032.
11. Zhang A, Liu Z, Sheng L, Wu H. J Surg Res. 2017; 209:252–257.
12. Kwon KS, Lee JH, So KS, Park BK, Lim H, Choi JS, Kim HP. Phytother Res. 2018; 32:1537–1545.
13. Zhu T, Zhang W, Feng SJ, Yu HP. Int Immunopharmacol. 2016; 34:16–24.
14. Yang MC, Kwon HC, Kim YJ, Lee KR, Yang HO. J Nat Prod. 2010; 73:801–805.
15. Kim SY, Son KH, Chang HW, Kang SS, Kim HP. Arch Pharm Res. 1997; 20:313–317.
16. Bihani GV, Rojatkar SR, Bodhankar SL. Biomed Aging Pathol. 2014; 4:197–206.
17. Srivastava S, Singh P, Jha KK, Mishra G, Srivastava S, Khosa RL. J Ayurveda Integr Med. 2012; 3:204–208.
Full Text Links
  • NPS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr